1
Clinical Trials associated with CART-PSMA-TGFβRDN cell therapy(Tmunity Therapeutics, Inc.)A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer
Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells (CART-PSMA-TGFβRDN cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T cell.
Start Date22 Nov 2019 |
Sponsor / Collaborator- |
100 Clinical Results associated with CART-PSMA-TGFβRDN cell therapy(Tmunity Therapeutics, Inc.)
100 Translational Medicine associated with CART-PSMA-TGFβRDN cell therapy(Tmunity Therapeutics, Inc.)
100 Patents (Medical) associated with CART-PSMA-TGFβRDN cell therapy(Tmunity Therapeutics, Inc.)
100 Deals associated with CART-PSMA-TGFβRDN cell therapy(Tmunity Therapeutics, Inc.)